InsightfulValue
← Home

Takeda Pharmaceutical
Takeda Pharmaceutical

Pharma / Pharmaceuticals, Healthcare


πŸ”§ Tools

βœ… Due Diligence
Company at a Glance

More reviews (2)
Takeda Pharmaceutical

πŸ“Š Get full analytics about Takeda Pharmaceutical

Sign up for free or log in

πŸ”“ Unlock our free guide: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

Price
Live  
Overview
Takeda Pharmaceutical Company Limited is a global, research-based pharmaceutical company headquartered in Japan. The company was founded in 1781 and has a rich history of over 200 years of continuous operation.
Takeda is one of the world's largest pharmaceutical companies, with a focus on developing and delivering innovative medicines to patients in more than 80 countries and regions around the world. The company's research and development efforts are focused on four therapeutic areas: oncology, gastroenterology, neurology, and rare diseases.
With a commitment to improving the health and well-being of people worldwide, Takeda strives to develop safe and effective medicines to treat a wide range of diseases and conditions. In addition to its core therapeutic areas, the company also has a growing portfolio in vaccines and consumer healthcare.
Takeda's corporate philosophy, "Takeda-ism," emphasizes its dedication to ethical and responsible business practices, as well as its commitment to patients, employees, and the global community.
Today, Takeda has a team of more than 49,000 employees worldwide, and its research and development efforts are led by a diverse network of scientists, researchers, and physicians who collaborate globally to drive innovation and advancement in the pharmaceutical industry.
What is special about the company?
Takeda Pharmaceutical

πŸ“ˆ Want to read more about Takeda Pharmaceutical?

Sign up for free or log in

πŸ’‘ Learn smarter stock picks with "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

VGhlcmUgYX JlIHNldmVy YWwgYXNwZW N0cyB0aGF0 IG1ha2UgVG FrZWRhIFBo YXJtYWNldX RpY2FsIHN0 YW5kIG91dC BhcyBhIGNv bXBhbnk6PG JyPjEuIExv bmcgSGlzdG 9yeTogVGFr ZWRhIFBoYX JtYWNldXRp Y2FsIHdhcy Bmb3VuZGVk IGluIDE3OD EsIG1ha2lu ZyBpdCBvbm Ugb2YgdGhl IG9sZGVzdC Bjb21wYW5p ZXMgaW4gSm FwYW4gYW5k IHRoZSB3b3 JsZC4gVGhp cyBsb25nIG hpc3Rvcnkg aGFzIGFsbG 93ZWQgdGhl IGNvbXBhbn kgdG8gZ2Fp biBleHRlbn NpdmUga25v d2xlZGdlIG FuZCBleHBl cmllbmNlIG luIHRoZSBw aGFybWFjZX V0aWNhbCBp bmR1c3RyeS 48YnI+Mi4g SW50ZXJuYX Rpb25hbCBQ cmVzZW5jZT ogVGFrZWRh IGhhcyBhIH N0cm9uZyBn bG9iYWwgcH Jlc2VuY2Us IHdpdGggb3 BlcmF0aW9u cyBpbiBvdm VyIDgwIGNv dW50cmllcy BhbmQgcmVn aW9ucyB3b3 JsZHdpZGUu IEl0IGhhcy BhIHN0cm9u ZyBmb2N1cy BvbiBlbWVy Z2luZyBtYX JrZXRzLCBl c3BlY2lhbG x5IGluIEFz aWEsIHdoZX JlIHRoZSBj b21wYW55IG hhcyBhIGxl YWRpbmcgcG 9zaXRpb24g aW4gdGhlIH BoYXJtYWNl dXRpY2FsIG luZHVzdHJ5 Ljxicj4zLi BEaXZlcnNl IFBvcnRmb2 xpbzogVGFr ZWRhIGhhcy BhIGRpdmVy c2UgcG9ydG ZvbGlvIG9m IHByb2R1Y3 RzLCBjb3Zl cmluZyBhIH dpZGUgcmFu Z2Ugb2YgdG hlcmFwZXV0 aWMgYXJlYX MsIGluY2x1 ZGluZyBvbm NvbG9neSwg Z2FzdHJvZW 50ZXJvbG9n eSwgbmV1cm 9zY2llbmNl LCByYXJlIG Rpc2Vhc2Vz LCBhbmQgdm FjY2luZXMu IFRoaXMgZG l2ZXJzaWZp Y2F0aW9uIG hlbHBzIHRo ZSBjb21wYW 55IG1pdGln YXRlIHJpc2 tzIGFuZCBt YWludGFpbi BhIHN0YWJs ZSByZXZlbn VlIHN0cmVh bS48YnI+NC 4gSW5ub3Zh dGlvbjogVG FrZWRhIGhh cyBhIHN0cm 9uZyBmb2N1 cyBvbiByZX NlYXJjaCBh bmQgZGV2ZW xvcG1lbnQg KFImRCksIH dpdGggYSBz aWduaWZpY2 FudCBpbnZl c3RtZW50IG luIGN1dHRp bmctZWRnZS B0ZWNobm9s b2d5IGFuZC Bjb2xsYWJv cmF0aW9ucy B3aXRoIGV4 dGVybmFsIH BhcnRuZXJz LiBUaGUgY2 9tcGFueSBh bHNvIGhhcy BhIHJvYnVz dCBwaXBlbG luZSBvZiBw b3RlbnRpYW wgbmV3IHRy ZWF0bWVudH MsIGVuc3Vy aW5nIGl0cy Bsb25nLXRl cm0gZ3Jvd3 RoLjxicj41 LiBDb3Jwb3 JhdGUgU29j aWFsIFJlc3 BvbnNpYmls aXR5OiBUYW tlZGEgaXMg Y29tbWl0dG VkIHRvIGNv cnBvcmF0ZS ByZXNwb25z aWJpbGl0eS BhbmQgaGFz IHNldCBhbW JpdGlvdXMg Z29hbHMgdG 8gcmVkdWNl IGl0cyBlbn Zpcm9ubWVu dGFsIGltcG FjdCBhbmQg aW1wcm92ZS BhY2Nlc3Mg dG8gaGVhbH RoY2FyZSBn bG9iYWxseS 4gVGhlIGNv bXBhbnkgYW xzbyBoYXMg dmFyaW91cy Bwcm9ncmFt cyBpbiBwbG FjZSB0byBz dXBwb3J0IG NvbW11bml0 aWVzIGFuZC Bwcm9tb3Rl IGRpdmVyc2 l0eSBhbmQg aW5jbHVzaW 9uLjxicj42 LiBWYWx1ZX MtRHJpdmVu IEN1bHR1cm U6IFRha2Vk YSdzIGNvcm UgdmFsdWVz LCBzdWNoIG FzICJpbnRl Z3JpdHksIG ZhaXJuZXNz LCBhbmQgaG 9uZXN0eSIg YW5kICJwdX R0aW5nIHRo ZSBwYXRpZW 50IGZpcnN0 LCIgYXJlIG RlZXBseSBp bmdyYWluZW QgaW4gaXRz IGNvcnBvcm F0ZSBjdWx0 dXJlLiBUaG lzIHN0cm9u ZyBldGhpY2 FsIGZvdW5k YXRpb24gZ3 VpZGVzIHRo ZSBjb21wYW 55J3MgZGVj aXNpb24tbW FraW5nIGFu ZCBkcml2ZX MgaXRzIGNv bW1pdG1lbn QgdG8gbWFr aW5nIGEgcG 9zaXRpdmUg aW1wYWN0IG luIHRoZSB3 b3JsZC48Yn I+SW4gY29u Y2x1c2lvbi wgVGFrZWRh IFBoYXJtYW NldXRpY2Fs J3MgbG9uZy BoaXN0b3J5 LCBnbG9iYW wgcHJlc2Vu Y2UsIGRpdm Vyc2UgcG9y dGZvbGlvLC Bmb2N1cyBv biBpbm5vdm F0aW9uLCBj b21taXRtZW 50IHRvIHNv Y2lhbCByZX Nwb25zaWJp bGl0eSwgYW 5kIHZhbHVl cy1kcml2ZW 4gY3VsdHVy ZSBhbGwgbW FrZSBpdCBh IHVuaXF1ZS BhbmQgc3Vj Y2Vzc2Z1bC Bjb21wYW55 IGluIHRoZS BwaGFybWFj ZXV0aWNhbC BpbmR1c3Ry eS4=
What the company's business model?
Takeda Pharmaceutical

πŸ“ˆ Want to read more about Takeda Pharmaceutical?

Sign up for free or log in

πŸ“˜ Claim your free eBook: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

VGhlIFRha2 VkYSBQaGFy bWFjZXV0aW NhbCBjb21w YW55J3MgYn VzaW5lc3Mg bW9kZWwgaX MgYmFzZWQg b24gcmVzZW FyY2hpbmcs IGRldmVsb3 BpbmcsIG1h bnVmYWN0dX JpbmcsIGFu ZCBtYXJrZX RpbmcgcGhh cm1hY2V1dG ljYWwgcHJv ZHVjdHMuIF RoZSBjb21w YW55IGZvY3 VzZXMgb24g dGhlIGZvbG xvd2luZyBr ZXkgYXJlYX M6PGJyPjEu IFJlc2Vhcm NoIGFuZCBk ZXZlbG9wbW VudDogVGFr ZWRhIGludm VzdHMgaGVh dmlseSBpbi ByZXNlYXJj aCBhbmQgZG V2ZWxvcG1l bnQgdG8gZG lzY292ZXIg YW5kIGRldm Vsb3AgbmV3 IG1lZGljaW 5lcyBmb3Ig ZGlzZWFzZX Mgd2l0aCBo aWdoIHVubW V0IG1lZGlj YWwgbmVlZH MuPGJyPjIu IE1hbnVmYW N0dXJpbmc6 IFRha2VkYS BoYXMgYSBn bG9iYWwgbm V0d29yayBv ZiBtYW51Zm FjdHVyaW5n IGZhY2lsaX RpZXMgdG8g cHJvZHVjZS BpdHMgcGhh cm1hY2V1dG ljYWwgcHJv ZHVjdHMgYX QgaGlnaCBx dWFsaXR5IG FuZCBlZmZp Y2llbmN5Lj xicj4zLiBN YXJrZXRpbm cgYW5kIHNh bGVzOiBUYW tlZGEgbWFy a2V0cyBhbm Qgc2VsbHMg aXRzIHByb2 R1Y3RzIHRv IGhlYWx0aG NhcmUgcHJv ZmVzc2lvbm FscyBhbmQg cGF0aWVudH MgZ2xvYmFs bHkgdGhyb3 VnaCB2YXJp b3VzIGNoYW 5uZWxzLCBp bmNsdWRpbm cgc2FsZXMg cmVwcmVzZW 50YXRpdmVz LCBkaWdpdG FsIG1hcmtl dGluZywgYW 5kIHBhcnRu ZXJzaGlwcy B3aXRoIGhl YWx0aGNhcm Ugb3JnYW5p emF0aW9ucy 48YnI+NC4g RGl2ZXJzaW ZpY2F0aW9u OiBUYWtlZG EgaGFzIGEg ZGl2ZXJzZS Bwb3J0Zm9s aW8gb2YgcG hhcm1hY2V1 dGljYWwgcH JvZHVjdHMs IHJhbmdpbm cgZnJvbSBw cmVzY3JpcH Rpb24gbWVk aWNpbmVzIH RvIG92ZXIt dGhlLWNvdW 50ZXIgYW5k IGNvbnN1bW VyIGhlYWx0 aGNhcmUgcH JvZHVjdHMu PGJyPjUuIE dlb2dyYXBo aWMgZXhwYW 5zaW9uOiBU YWtlZGEgb3 BlcmF0ZXMg aW4gb3Zlci A4MCBjb3Vu dHJpZXMgYW 5kIGNvbnRp bnVlcyB0by BleHBhbmQg aXRzIHByZX NlbmNlIGlu IGVtZXJnaW 5nIG1hcmtl dHMsIHBhcn RpY3VsYXJs eSBpbiBBc2 lhIGFuZCBM YXRpbiBBbW VyaWNhLjxi cj42LiBTdH JhdGVnaWMg cGFydG5lcn NoaXBzIGFu ZCBhY3F1aX NpdGlvbnM6 IFRha2VkYS Bjb2xsYWJv cmF0ZXMgd2 l0aCBvdGhl ciBwaGFybW FjZXV0aWNh bCBjb21wYW 5pZXMgYW5k IHJlc2Vhcm NoIGluc3Rp dHV0aW9ucy B0byBkZXZl bG9wIG5ldy B0cmVhdG1l bnRzIGFuZC B0ZWNobm9s b2dpZXMuIF RoZSBjb21w YW55IGFsc2 8gYWNxdWly ZXMgb3RoZX IgY29tcGFu aWVzIHRvIG V4cGFuZCBp dHMgcHJvZH VjdCBwb3J0 Zm9saW8gYW 5kIGdlb2dy YXBoaWMgcm VhY2guPGJy PjcuIFBhdG llbnQtY2Vu dHJpYyBhcH Byb2FjaDog VGFrZWRhIG ZvY3VzZXMg b24gdW5kZX JzdGFuZGlu ZyBwYXRpZW 50cycgbmVl ZHMgYW5kIH dvcmtzIHRv IGRldmVsb3 AgdHJlYXRt ZW50cyB0aG F0IG1lZXQg dGhvc2Ugbm VlZHMuIFRo ZSBjb21wYW 55IGFsc28g aW52ZXN0cy BpbiBwYXRp ZW50IGVkdW NhdGlvbiBh bmQgYWNjZX NzIHByb2dy YW1zIHRvIG 1ha2UgdHJl YXRtZW50cy Btb3JlIGFj Y2Vzc2libG UgdG8gdGhv c2UgaW4gbm VlZC48YnI+ T3ZlcmFsbC wgVGFrZWRh J3MgYnVzaW 5lc3MgbW9k ZWwgaXMgY2 VudGVyZWQg b24gaW5ub3 ZhdGlvbiwg c3RyYXRlZ2 ljIHBhcnRu ZXJzaGlwcy wgYW5kIGEg cGF0aWVudC 1jZW50cmlj IGFwcHJvYW NoIHRvIGJy aW5nIGxpZm UtY2hhbmdp bmcgbWVkaW NpbmVzIHRv IHBlb3BsZS Bhcm91bmQg dGhlIHdvcm xkLg==
Interesting facts about the company
Takeda Pharmaceutical

πŸ“ˆ Want to read more about Takeda Pharmaceutical?

Sign up for free or log in

πŸš€ Don’t miss "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" β€” free!

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvVz hVeWd5Y2dj ekVBMVhsRE 5nNjIud2Vi cCIgYWx0PS JUYWtlZGEg UGhhcm1hY2 V1dGljYWwi IHRpdGxlPS JUYWtlZGEg UGhhcm1hY2 V1dGljYWwi ICBjbGFzcz 0iaW1nLWZs dWlkIiBoZW lnaHQ9OTAg d2lkdGg9OT AgbG9hZGlu Zz0nbGF6eS cgc3R5bGU9 J2JvcmRlci 1yYWRpdXM6 IDZweDsnPg oKICAgICAg ICAgICAgIC AgICAgICA8 ZGl2IHN0eW xlPSdmbGV4 OiAxOyB0ZX h0LWFsaWdu OiBjZW50ZX I7IG1hcmdp bi1sZWZ0Oi A1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPHAgc3R5 bGU9J2Zvbn Qtc2l6ZTog MjZweDsgY2 9sb3I6ICMz MzM7IG1hcm dpbi1ib3R0 b206IDE1cH g7Jz4KICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIPCfk4gg V2FudCB0by ByZWFkIG1v cmUgYWJvdX QgVGFrZWRh IFBoYXJtYW NldXRpY2Fs PwogICAgIC AgICAgICAg ICAgICAgIC AgICA8L3A+ CgogICAgIC AgICAgICAg ICAgICAgIC AgICA8YSBo cmVmPSdpbm RleC5waHA/ cGFnZT1zaW dudXAnIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGJhY2 tncm91bmQt Y29sb3I6IC MwMDdCRkY7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBj b2xvcjogI2 ZmZjsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH ggMjBweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIGJv cmRlci1yYW RpdXM6IDVw eDsKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IHRleHQtZG Vjb3JhdGlv bjogbm9uZT sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG ZvbnQtd2Vp Z2h0OiBib2 xkOwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgbWFyZ2lu LXJpZ2h0Oi AxMHB4Owog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgdHJh bnNpdGlvbj ogYmFja2dy b3VuZC1jb2 xvciAwLjNz IGVhc2U7Jw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgb2 5tb3VzZW92 ZXI9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA1Nm IzIicKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIG9ubW91 c2VvdXQ9J3 RoaXMuc3R5 bGUuYmFja2 dyb3VuZENv bG9yPSIjMD A3QkZGIic+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBT aWduIHVwIG ZvciBmcmVl CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvYT4K CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDxzcGFu IHN0eWxlPS dtYXJnaW46 IDAgOHB4Oy Bjb2xvcjog IzU1NTsnPm 9yPC9zcGFu PgoKICAgIC AgICAgICAg ICAgICAgIC AgICAgPGEg aHJlZj0naW 5kZXgucGhw P3BhZ2U9bG 9naW4nIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGNvbG 9yOiAjMDA3 QkZGOwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgdGV4dC 1kZWNvcmF0 aW9uOiB1bm RlcmxpbmU7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBm b250LXdlaW dodDogNTAw Oyc+CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICBsb2cgaW 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9hPg oKCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxwIH N0eWxlPSdt YXJnaW4tdG 9wOiAxNXB4 OyBmb250LX NpemU6IDEz cHg7IGZvbn Qtd2VpZ2h0 OiBib2xkOy Bjb2xvcjog I2QzMmYyZj snPgogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Ag8J+OgSBG cmVlIGRvd2 5sb2FkISA8 aT4iVGhlIE NoZWNrbGlz dCBWYWx1ZS BJbnZlc3Rv ciDigJQgQS BTbWFydGVy IFdheSB0by BQaWNrIFN0 b2NrcyI8L2 k+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIDwvcD 4KCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDwhLS 0KICAgICAg ICAgICAgIC AgICAgICAg ICAgPGRpdi BzdHlsZT0n bWFyZ2luLX RvcDogMTJw eDsgZm9udC 1zaXplOiAx M3B4OyBjb2 xvcjogIzQ0 NDsnPgogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgU2lnbi B1cCBub3cg YW5kIGdldC BvdXIgZnJl ZSBlQm9vay AKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgID xiPlRoZSBD aGVja2xpc3 QgVmFsdWUg SW52ZXN0b3 Ig4oCUIEEg U21hcnRlci BXYXkgdG8g UGljayBTdG 9ja3M8L2I+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvZGl2 PgogICAgIC AgICAgICAg ICAgICAgIC AgICAtLT4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPCEtLQog ICAgICAgIC AgICAgICAg ICAgICAgIC A8ZGl2IHN0 eWxlPSdtYX JnaW4tdG9w OiAxNnB4Oy Bmb250LXNp emU6IDE0cH g7IGNvbG9y OiAjNDQ0Oy Bmb250LWZh bWlseTogLW FwcGxlLXN5 c3RlbSwgQm xpbmtNYWNT eXN0ZW1Gb2 50LCBTZWdv ZSBVSSwgUm 9ib3RvLCBI ZWx2ZXRpY2 EgTmV1ZSwg c2Fucy1zZX JpZjsgbGlu ZS1oZWlnaH Q6IDEuNjsn PgogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg SGF2ZSB5b3 UgaGVhcmQg YWJvdXQgb3 VyIHNob3J0 IDxzdHJvbm cgc3R5bGU9 J2ZvbnQtd2 VpZ2h0OiA2 MDA7Jz5EYW lseSBWaWRl byBOZXdzbG V0dGVyPC9z dHJvbmc+Pw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgPG EgaHJlZj0n aHR0cHM6Ly 93d3cuaW5z aWdodGZ1bH ZhbHVlLmNv bS9uZXdzbG V0dGVyLnBo cCcgdGFyZ2 V0PSdfYmxh bmsnIHN0eW xlPSdjb2xv cjogIzAwN0 JGRjsgdGV4 dC1kZWNvcm F0aW9uOiBu b25lOyBmb2 50LXdlaWdo dDogNTAwOy BtYXJnaW4t bGVmdDogNn B4Oyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg RmluZCBvdX QgbW9yZQog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgPC9h PgogICAgIC AgICAgICAg ICAgICAgIC AgICA8L2Rp dj4KICAgIC AgICAgICAg ICAgICAgIC AgICAgLS0+ CiAgICAgIC AgICAgICAg ICAgICAgPC 9kaXY+CiAg ICAgICAgIC AgICAgICA8 L2Rpdj4KIC AgICAgICAg ICAgPC9kaX Y+CiAgICAg ICAgICAgIA ogICAgICAg IAogICAgIC AgIDxzcGFu IGNsYXNzPS dibHVycmVk LXRleHQnPg ogICAgICAg ICAgICBNUz RnVkdGclpX IFJoSUZCb1 lYSnQgWVdO bGRYUnBZMi BGc0lHbHpJ R0VnIFNtRn dZVzVsYzIg VWdiWFZzZE dsdSBZWFJw YjI1aGJDIE J3YUdGeWJX RmogWlhWMG FXTmhiQyBC amIyMXdZVz U1IExDQm9a V0ZrY1ggVm hjblJsY21W ayBJR2x1SU ZSdmEzIGx2 TENCS1lYQm ggYmk0Z1NY UWdhWCBNZ2 IyNWxJRzlt IElIUm9aU0 JzWVggSm5a WE4wSUhCby BZWEp0WVdO bGRYIFJwWT JGc0lHTnYg YlhCaGJtbG xjeSBCcGJp QjBhR1VnIG QyOXliR1Fn WW4ga2djbV YyWlc1MSBa UzQ4WW5JK0 1pIDRnVkdo bElHTnYgYl hCaGJua2dk MiBGeklHWn ZkVzVrIFpX UWdhVzRnTV QgYzRNU0Jp ZVNCRCBhRz lpWldrZ1ZH IEZyWldSaE lFa2cgWVc1 a0lIZGhjeS BCcGJtbDBh V0ZzIGJIa2 dZMkZzYkcg VmtJRlJoYT JWayBZU0JE YUc5aVpXIG tnVUdoaGNt MWggWTJWMW RHbGpZVyB3 Z1UyaHZjQz RnIFNYUWdk MkZ6SUcgRW djMjFoYkd3 ZyBjR2hoY2 0xaFkzIGtn YVc0Z1JHOX ogYUc5dFlX Tm9hUyB3Z1 QzTmhhMkVz IElFcGhjR0 Z1TGogeGlj ajR6TGlCVS BZV3RsWkdF Z1VHIGhoY2 0xaFkyVjEg ZEdsallXd2 dZbSBWallX MWxJR0VnIG NIVmliR2xq SUcgTnZiWE JoYm5rZyBh VzRnTVRrME 9TIEJoYm1R Z2QyRnogSU d4cGMzUmxa QyBCdmJpQj BhR1VnIFZH OXJlVzhnVT MgUnZZMnNn UlhoaiBhR0 Z1WjJVdVBH IEp5UGpRdU lGUmggYTJW a1llS0FtWC BNZ2JXRnBi aUJtIGIyTj FjeUJwY3kg QnlaWE5sWV hKaiBhQ0Jo Ym1RZ1pHIF YyWld4dmNH MWwgYm5RZ2 FXNGdkRyBo bElHWnBaV3 hrIGN5QnZa aUJ2Ym0gTn ZiRzluZVN3 ZyBaMkZ6ZE hKdlpXIDUw WlhKdmJHOW 4gZVN3Z1lX NWtJRyBObG JuUnlZV3dn IGJtVnlkbT kxY3kgQnpl WE4wWlcwZy BaR2x6YjNK a1pYIEp6TG lCSmRDQmgg YkhOdklIQn liMiBSMVky VnpJSFpoIF kyTnBibVZ6 SUcgRnVaQ0 J2ZG1WeSBM WFJvWlMxam IzIFZ1ZEdW eUlHMWwgWk dsallYUnBi MiA1ekxqeG ljajQxIExp QlVhR1VnWT IgOXRjR0Z1 ZVNCbyBZWE 1nWVNCbmJH IDlpWVd3Z2 NISmwgYzJW dVkyVXNJSC BkcGRHZ2di M0JsIGNtRj BhVzl1Y3kg QnBiaUJ2ZG 1WeSBJRGd3 SUdOdmRXID UwY21sbGN5 QmggYm1RZ2 NtVm5hVyA5 dWN5d2dhVz VqIGJIVmth VzVuSUggUm 9aU0JWYm1s MCBaV1FnVT NSaGRHIFZ6 TENCRmRYSn YgY0dVc0lH RnVaQyBCQm MybGhManhp IGNqNDJMaU JVWVcgdGxa R0VnYUdGei BJR0VnYzNS eWIyIDVuSU dOdmJXMXAg ZEcxbGJuUW dkRyA4Z2Mz VnpkR0ZwIG JtRmlhV3hw ZEgga2dZVz VrSUhkaCBj eUJzYVhOMF pXIFFnYVc0 Z2RHaGwgSU VSdmR5Qkti MiA1bGN5Ql RkWE4wIFlX bHVZV0pwYk cgbDBlU0JK Ym1ScCBZMl Z6SUdadmNp IEF4TVNCam IyNXogWldO MWRHbDJaUy BCNVpXRnlj eTQ4IFluSS tOeTRnU1cg NGdNakF3T0 N3ZyBWR0Zy WldSaElHIE ZqY1hWcGNt VmsgSUUxcG JHeGxibSA1 cGRXMGdVR2 hoIGNtMWhZ MlYxZEcgbG pZV3h6TENC aCBJR3hsWV dScGJtIGNn WW1sdmNHaG ggY20xaFky VjFkRyBsal lXd2dZMjl0 IGNHRnVlU0 JtYjIgTjFj MlZrSUc5dS BJSFJvWlNC a1pYIFpsYk c5d2JXVnUg ZENCdlppQn ZibSBOdmJH OW5lU0IwIG NtVmhkRzFs Ym4gUnpMan hpY2o0NCBM aUJVWVd0bF pHIEVnYVhN Z2FXNTIgYj J4MlpXUWdh VyA0Z2RtRn lhVzkxIGN5 QndZWEowYm 0gVnljMmhw Y0hNZyBZVz VrSUdOdmJH IHhoWW05eV lYUnAgYjI1 eklIZHBkRy BnZ2IzUm9a WElnIGNHaG hjbTFoWTIg VjFkR2xqWV d3ZyBZMjl0 Y0dGdWFXIF Z6TENCaFky RmsgWlcxcF l5QnBibiBO MGFYUjFkR2 x2IGJuTXNJ R0Z1WkMgQn laWE5sWVhK aiBhQ0J2Y2 1kaGJtIGw2 WVhScGIyNX ogTGp4aWNq NDVMaSBCVW FHVWdZMjl0 IGNHRnVlU0 JoYkggTnZJ R2hoY3lCaC BJSE4wY205 dVp5IEJtYj JOMWN5QnYg YmlCcGJtNX ZkbSBGMGFX OXVJR0Z1IF pDQnBiblps YzMgUnpJR2 hsWVhacCBi SGtnYVc0Z2 NtIFZ6WldG eVkyZ2cgWV c1a0lHUmxk bSBWc2IzQn RaVzUwIExp QkpiaUF5TU QgSXdMQ0Jw ZENCeiBjR1 Z1ZENCdmRt IFZ5SUNRME lHSnAgYkd4 cGIyNGdiMi A0Z1VpWkVM anhpIGNqNH hNQzRnVkcg RnJaV1JoSU doaCBjeUJo SUhKcFkyIG dnYUdsemRH OXkgZVNCaG JtUWdhRyBG eklIQnNZWG xsIFpDQmhJ SE5wWjIgNX BabWxqWVc1 MCBJSEp2Yk dVZ2FXIDRn ZEdobElHUm wgZG1Wc2Iz QnRaVyA1ME lHOW1JSFJv IFpTQndhR0 Z5YlcgRmpa WFYwYVdOaC BiQ0JwYm1S MWMzIFJ5ZV NCcGJpQksg WVhCaGJpNG dTWCBRZ2FH RnpJR0psIF pXNGdjbVZq YjIgZHVhWH BsWkNCMyBh WFJvSUc1MW JXIFZ5YjNW eklHRjMgWV hKa2N5Qmhi bSBRZ2FHOX ViM0p6IElH OTJaWElnZE cgaGxJSGxs WVhKeiBMan hpY2o0eE1T IDRnVkdGcl pXUmggSUdo aGN5QmhJRy BOdmNuQnZj bUYwIFpTQn dhR2xzYjMg TnZjR2g1SU dOaCBiR3hs WkNCVVlXIH RsWkdFdGFY TnQgTENCM2 FHbGphQyBC bGJYQm9ZWE 5wIGVtVnpJ SFJvWlMgQm piMjF3WVc1 NSA0b0NaY3 lCamIyIDF0 YVhSdFpXNT AgSUhSdklI QmhkRyBsbG JuUnpMQ0Js IGJYQnNiM2 xsWlggTXNJ R0Z1WkNCei BiMk5wWlhS NUxqIHhpY2 o0eE1pNGcg VkdobElHTn ZiWCBCaGJu a2dhR0Z6IE lHWmhZMlZr SUcgTm9ZV3 hzWlc1biBa WE1nYVc0Z2 NtIFZqWlc1 MElIbGwgWV hKekxDQnBi bSBOc2RXUn BibWNnIGNH RjBaVzUwSU cgVjRjR2x5 WVhScCBiMj V6SUdGdVpD IEJzWldkaG JDQnAgYzNO MVpYTWdjbS BWbllYSmth VzVuIElITn ZiV1VnYjIg WWdhWFJ6SU cxbCBaR2xq WVhScGIyID V6TGlCSWIz ZGwgZG1WeU xDQnBkQyBC amIyNTBhVz UxIFpYTWdk RzhnWW0gVW dZU0J0WVdw diBjaUJ3Yk dGNVpYIEln YVc0Z2RHaG wgSUdkc2Iy SmhiQyBCd2 FHRnliV0Zq IFpYVjBhV0 5oYkMgQnRZ WEpyWlhRdS BQR0p5UGpF ekxpIEJKYm lBeU1ESXgg TENCVVlXdG xaRyBFZ1lX NXViM1Z1IF kyVmtJR2ww Y3kgQnBibl JsYm5ScCBi MjRnZEc4Z1 ltIFZqYjIx bElHRWcgWj J4dlltRnNJ RyB4bFlXUm xjaUJwIGJp QnlZWEpsSU cgUnBjMlZo YzJWeiBJSG RwZEdnZ1lT IEJuYjJGc0 lIUnYgSUd4 aGRXNWphQy BBek1DQnlZ WEpsIElHUn BjMlZoYzIg VWdkR2hsY2 1GdyBhV1Z6 SUdKNUlEIE l3TXpBdVBH SnkgUGpFME xpQlVZVyB0 bFpHRWdhWE 1nIFlXeHpi eUJyYm0gOT NiaUJtYjNJ ZyBhWFJ6SU hOMGNtIDl1 WnlCamIzSn cgYjNKaGRH VWdZMyBWc2 RIVnlaU0Jo IGJtUWdhR0 Z6SUcgSmxa VzRnY21Wai BiMmR1YVhw bFpDIEJoY3 lCdmJtVWcg YjJZZ2RHaG xJSCBkdmNt eGs0b0NaIG N5QnRiM04w SUcgRmtiV2 x5WldRZyBZ Mjl0Y0dGdW FXIFZ6SUdK NUlFWnYgY2 5SMWJtVWdU VyBGbllYcH BibVVnIFpt OXlJREV3SU cgTnZibk5s WTNWMCBhWF psSUhsbFlY IEp6TGp4aW NqNHggTlM0 Z1NXNGdZVy BSa2FYUnBi MjRnIGRHOG djR2hoY20g MWhZMlYxZE dsaiBZV3h6 TENCVVlXIH RsWkdFZ2FY TWcgWVd4em J5QnBibiBa dmJIWmxaQ0 JwIGJpQjJZ WEpwYjMgVn pJRzkwYUdW eSBJR0oxYz JsdVpYIE56 WlhNc0lHbH UgWTJ4MVpH bHVaeSBCbW IyOWtJSEJ5 IGIyUjFZM1 J6TEMgQm9a V0ZzZEdnZy BZVzVrSUdK bFlYIFYwZV NCemRYQncg YkdWdFpXNT BjeSB3Z1lX NWtJRzFsIF pHbGpZV3dn WkcgVjJhV0 5sY3k0PQog ICAgICAgID wvc3Bhbj4K ICAgICAgIC AKICAgICAg ICA=
See Company Q&A
Takeda Pharmaceutical

πŸ“Š Get full analytics about Takeda Pharmaceutical

Sign up for free or log in

πŸš€ Don’t miss "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" β€” free!

© 2024 - 2025 InsightfulValue.com. All rights reserved. Newsletter
Legal